Attached files
file | filename |
---|---|
8-K - CHINA-BIOTICS, INC | v205499_8k.htm |
China-Biotics,
Inc. to Hold 2010 Annual
Meeting
of Stockholders on March 9, 2011
Shanghai, China – December 15,
2010 – China-Biotics, Inc. ("China-Biotics" or "the Company"), (NASDAQ:
CHBT) the leading developer, manufacturer, and distributor of probiotics
products in China, today announced that the Company’s 2010 Annual Meeting of
Stockholders (the “Annual Meeting”) will be held on Wednesday, March 9, 2011, at
10:30 a.m. (Shanghai time). The Annual Meeting will be held at the
Company’s executive offices at No. 26, Orient Global Headquarter, Lane 118,
Yonghe Road, Zhabei District, Shanghai 200072, People’s Republic of China. The
Company’s Board of Directors has established Tuesday, January 25, 2011, as the
record date for determining stockholders entitled to vote at the Annual Meeting,
and management expects that the proxy statement for the Annual Meeting will be
mailed to stockholders on or about Friday, January 28, 2011.
Stockholder
proposals must be received no later than Friday, January 14, 2011, in order to
be considered for inclusion in the Company’s proxy statement or to be presented
at the Annual Meeting. Stockholder proposals should be mailed to: No.
26, Orient Global Headquarter, Lane 118, Yonghe Road, Zhabei District, Shanghai
200072, People’s Republic of China, Attn: Corporate Secretary.
About
China-Biotics
China-Biotics,
Inc. ("China-Biotics" or "the Company"), a leading manufacturer of biotechnology
products and supplements, engages in the research, development, marketing and
distribution of probiotics dietary supplements in China. Through its wholly
owned subsidiaries, Shanghai Shining Biotechnology Co., Ltd. and Growing
Bioengineering (Shanghai) Co. Ltd., the Company develops and produces a
proprietary product portfolio. Currently, its retail products are sold over the
counter, mainly through large distributors, to pharmacies and supermarkets in
Shanghai, Jiangsu, and Zhejiang provinces. The Company also sells bulk products
to institutional customers such as dairy and animal feed producers, as well as
pharmaceutical companies. In February 2010, China-Biotics began its commercial
production in China's largest probiotics production facility to meet the growing
demand in China. For more information, please visit
http://www.chn-biotics.com.
Safe
Harbor Statement
The
information in this release contains forward-looking statements which involve
risks and uncertainties, including statements regarding the Company's capital
needs, business strategy and expectations. Any statements contained herein that
are not statements of historical fact may be deemed to be forward-looking
statements, which may be identified by terminology such as "may," "should,"
"will," "expect," "plan," "intend," "anticipate," "believe," "estimate,"
"predict," "potential," "forecast," "project," or "continue," the negative of
such terms or other comparable terminology. Readers should not rely on
forward-looking statements as predictions of future events or results. Any or
all of the Company's forward-looking statements may turn out to be wrong. They
can be affected by inaccurate assumptions, risks and uncertainties and other
factors which could cause actual events or results to be materially different
from those expressed or implied in the forward-looking statements. In evaluating
these statements, readers should consider various factors, including the risks
described in "Item 1A. Risk Factors" beginning on page 17 and elsewhere in the
Company's 2010 Annual Report on Form 10-K. These factors may cause the Company's
actual results to differ materially from any forward-looking statement. In
addition, new factors emerge from time to time and it is not possible for the
Company to predict all factors that may cause actual results to differ
materially from those contained in any forward- looking statements. The Company
disclaims any obligation to publicly update any forward-looking statements to
reflect events or circumstances after the date of this document, except as
required by applicable law.
Contact:
Travis
Cai
Chief
Financial Officer
China-Biotics,
Inc.
traviscai@chn-biotics.com
Shiwei
Yin/Dixon Chen
Grayling
646-284-9474
shiwei.yin@grayling.com
dixon.chen@grayling.com